37111372|t|Brain Kynurenine Pathway Metabolite Levels May Reflect Extent of Neuroinflammation in ALS, FTD and Early Onset AD.
37111372|a|OBJECTIVES: Despite distinct clinical profiles, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) patients share a remarkable portion of pathological features, with a substantial percentage of patients displaying a mixed disease phenotype. Kynurenine metabolism seems to play a role in dementia-associated neuroinflammation and has been linked to both diseases. We aimed to explore dissimilarities in kynurenine pathway metabolites in these early onset neurodegenerative disorders in a brain-region-specific manner. METHODS: Using liquid chromatography mass spectrometry (LC-MS/MS), kynurenine metabolite levels were determined in the brain samples of 98 healthy control subjects (n = 20) and patients with early onset Alzheimer's disease (EOAD) (n = 23), ALS (n = 20), FTD (n = 24) or a mixed FTD-ALS (n = 11) disease profile. RESULTS: Overall, the kynurenine pathway metabolite levels were significantly lower in patients with ALS compared to FTD, EOAD and control subjects in the frontal cortex, substantia nigra, hippocampus and neostriatum. Anthranilic acid levels and kynurenine-to-tryptophan ratios were consistently lower in all investigated brain regions in ALS compared to the other diagnostic groups. CONCLUSIONS: These results suggest that the contribution of kynurenine metabolism in neuroinflammation is lower in ALS than in FTD or EOAD and may also be traced back to differences in the age of onset between these disorders. Further research is necessary to confirm the potential of the kynurenine system as a therapeutic target in these early onset neurodegenerative disorders.
37111372	6	16	Kynurenine	Chemical	MESH:D007737
37111372	65	82	Neuroinflammation	Disease	MESH:D000090862
37111372	86	89	ALS	Disease	MESH:D000690
37111372	91	94	FTD	Disease	MESH:D057180
37111372	111	113	AD	Disease	MESH:D000544
37111372	163	192	amyotrophic lateral sclerosis	Disease	MESH:D000690
37111372	194	197	ALS	Disease	MESH:D000690
37111372	203	226	frontotemporal dementia	Disease	MESH:D057180
37111372	228	231	FTD	Disease	MESH:D057180
37111372	233	241	patients	Species	9606
37111372	328	336	patients	Species	9606
37111372	375	385	Kynurenine	Chemical	MESH:D007737
37111372	421	429	dementia	Disease	MESH:D003704
37111372	441	458	neuroinflammation	Disease	MESH:D000090862
37111372	536	546	kynurenine	Chemical	MESH:D007737
37111372	588	615	neurodegenerative disorders	Disease	MESH:D019636
37111372	718	728	kynurenine	Chemical	MESH:D007737
37111372	828	836	patients	Species	9606
37111372	854	873	Alzheimer's disease	Disease	MESH:D000544
37111372	875	879	EOAD	Disease	MESH:D000544
37111372	891	894	ALS	Disease	MESH:D000690
37111372	905	908	FTD	Disease	MESH:D057180
37111372	929	932	FTD	Disease	MESH:D057180
37111372	933	936	ALS	Disease	MESH:D000690
37111372	985	995	kynurenine	Chemical	MESH:D007737
37111372	1050	1058	patients	Species	9606
37111372	1064	1067	ALS	Disease	MESH:D000690
37111372	1080	1083	FTD	Disease	MESH:D057180
37111372	1085	1089	EOAD	Disease	MESH:D000544
37111372	1181	1197	Anthranilic acid	Chemical	MESH:C031385
37111372	1209	1219	kynurenine	Chemical	MESH:D007737
37111372	1223	1233	tryptophan	Chemical	MESH:D014364
37111372	1302	1305	ALS	Disease	MESH:D000690
37111372	1407	1417	kynurenine	Chemical	MESH:D007737
37111372	1432	1449	neuroinflammation	Disease	MESH:D000090862
37111372	1462	1465	ALS	Disease	MESH:D000690
37111372	1474	1477	FTD	Disease	MESH:D057180
37111372	1481	1485	EOAD	Disease	MESH:D000544
37111372	1636	1646	kynurenine	Chemical	MESH:D007737
37111372	1699	1726	neurodegenerative disorders	Disease	MESH:D019636
37111372	Negative_Correlation	MESH:C031385	MESH:D000690
37111372	Association	MESH:D014364	MESH:D000690
37111372	Negative_Correlation	MESH:D007737	MESH:D000690
37111372	Association	MESH:D007737	MESH:D003704
37111372	Association	MESH:D007737	MESH:D000090862
37111372	Association	MESH:D007737	MESH:D019636

